Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 16.3 MB, PDF document
We generated ex vivo drug-response and multiomics profiling data for a prospective series of 252 samples from 186 patients with acute myeloid leukemia (AML). A functional precision medicine tumor board (FPMTB) integrated clinical, molecular, and functional data for application in clinical treatment decisions. Actionable drugs were found for 97% of patients with AML, and the recommendations were clinically implemented in 37 relapsed or refractory patients. We report a 59% objective response rate for the individually tailored therapies, including 13 complete responses, as well as bridging five patients with AML to allogeneic hematopoietic stem cell transplantation. Data integration across all cases enabled the identification of drug response biomarkers, such as the association of IL15 overexpression with resistance to FLT3 inhibitors. Integration of molecular profiling and large-scale drug response data across many patients will enable continuous improvement of the FPMTB recommen-dations, providing a paradigm for individualized implementation of functional precision cancer medicine.
Original language | English |
---|---|
Journal | Cancer Discovery |
Volume | 12 |
Issue number | 2 |
Pages (from-to) | 388-401 |
Number of pages | 14 |
ISSN | 2159-8274 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© 2021 The Authors; Published by the American Association for Cancer Research.
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 298119708